Ondrej Sorejs1,2, Milos Pesek3, Jindrich Finek1, Ondrej Fiala1,2. 1. Department of Oncology and Radiotherapy, Medical School and Teaching Hospital Pilsen, Charles University Prague, Czech Republic. 2. Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Czech Republic. 3. Department of Pneumology, Medical School and Teaching Hospital Pilsen, Charles University Prague, Czech Republic.
Abstract
Thymomas are the most common mediastinal tumors. Systemic therapy for patients with unresectable or recurrent thymomas is a challenging field in the current oncology research. There is some evidence that somatostatin analogs combined with corticosteroids may have a role in the treatment of advanced malignant thymoma; however, the role of these agents have not been fully evaluated. CASE REPORT: A 39-year-old man with metastatic thymoma was administered long-acting depot injection form of octreotide. Octreotide scan before the treatment initiation revealed low uptake. CT control after three months of the treatment revealed marked regression of pleural metastases, while the primary tumor mass remained stable. The treatment response was lasting for 9 months. CONCLUSION: We describe an interesting case of marked clinical and radiological response of advanced malignant thymoma to the treatment with octreotide in a heavily pre-treated patient, even though octreotide scan revealed low uptake.
Thymomas are the most common mediastinal tumors. Systemic therapy for patients with unresectable or recurrent thymomas is a challenging field in the current oncology research. There is some evidence that somatostatin analogs combined with corticosteroids may have a role in the treatment of advanced malignant thymoma; however, the role of these agents have not been fully evaluated. CASE REPORT: A 39-year-old man with metastatic thymoma was administered long-acting depot injection form of octreotide. Octreotide scan before the treatment initiation revealed low uptake. CT control after three months of the treatment revealed marked regression of pleural metastases, while the primary tumor mass remained stable. The treatment response was lasting for 9 months. CONCLUSION: We describe an interesting case of marked clinical and radiological response of advanced malignant thymoma to the treatment with octreotide in a heavily pre-treated patient, even though octreotide scan revealed low uptake.
Authors: D Ferone; M P van Hagen; D J Kwekkeboom; P M van Koetsveld; D M Mooy; E Lichtenauer-Kaligis; A Schönbrunn; A Colao; S W Lamberts; L J Hofland Journal: J Clin Endocrinol Metab Date: 2000-04 Impact factor: 5.958
Authors: Giovannella Palmieri; Liliana Montella; Angelo Martignetti; Pietro Muto; Dolores Di Vizio; Annarosaria De Chiara; Secondo Lastoria Journal: Cancer Date: 2002-03-01 Impact factor: 6.860